Astellas Gene Therapies
NEWS
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.
It is planned to go into operation in 2021, and is expected to create more than 200 new jobs in Lee County, North Carolina.
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
San Francisco-based Audentes Therapeutics signed a licensing agreement and collaboration deal with Nationwide Children’s Hospital to expand its pipeline for vectorized antisense treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Maryland-based REGENXBIO is expanding its gene therapy pipeline to include a new treatment for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease.
JOBS
IN THE PRESS